Risk-adapted approach to prostate cancer screening

• Main Authors: A. A. Kirichek, L. N. Lyubchenko, V. B. Matveev
• Format: Article
• Language: Russian
• Published: ABV-press 2018-07-01
• Series: Onkourologiâ
• Subjects: prostate cancer; family history; germline mutation; brca1; brca2; hoxb13; chek2; lynch syndrome; targeted screening
• Online Access: https://oncourology.abvpress.ru/oncur/article/view/832

Mass prostatic specific antigen (PSA) testing (population-based PSA screening) has remained controversial, nevertheless there are men cohorts likely to benefit from PSA screening. Heritable factors contribute to 60 % risk for developing familial prostate cancer. Despite the fact that its clinical application is challenging due to polygenic inheritance, advances in new generation sequencing technologies permit identifying highly penetrant germline mutations in genes BRCA1, BRCA2, CHEK2, HOXB13 and MMR associated with tremendous increase in risk of developing the prostate cancer. Several germline mutations are associated with clinically aggressiveness of disease and shortened survival. Targeted screening that is based on family history and genomic aberrations should be the next step towards the precision medicine. Men at elevated risk should been performed for early detection are those with familiar history of prostate cancer, or BRCA1, BRCA2, CHEK2, HOXB13 and MMR pathogenic germline mutation carriers, or first line relatives diagnosed with certain types of cancer. Systematic PSA testing in 1–2 years among germline mutation carriers men beginning at age 45 years would contribute to increase in early detection of localized prostate cancer resulting in more chance of curative treatment and improve survival rates